Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Forsythin (also known as Phillyrin) is a bioactive lignan glycoside extracted from the fruit of the medicinal plant Forsythia suspensa. It is considered an active ingredient in traditional herbal medicine and has been investigated for its potential anti-inflammatory and antiviral properties. Preclinical studies suggest that forsythin may modulate several cellular signaling pathways related to inflammation and immune response, including PI3K/Akt/mTOR and JAK/STAT pathways[3]. Clinical development in China has reached phase 2 trials for indications such as common cold, influenza, fever, and pharyngitis[4]. The precise mechanism of action remains unclear; no specific molecular targets have been conclusively identified.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on forsythin.